CGS-CIMB sees decent earnings growth for Pharmaniaga, reiterates ‘add’ call

  • 📰 malaymail
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 10%
  • Publisher: 86%

United States News News

United States United States Latest News,United States United States Headlines

KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd (CGS-CIMB) is positive on Pharmaniaga Bhd (Pharmaniaga) on the expectation of a decent financial year 2023-2024 (FY23-24)...

KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd is positive on Pharmaniaga Bhd on the expectation of a decent financial year 2023-2024 earnings growth for the company.

“The ample excess production capacity at Pharmaniaga’s existing plants will allow it to ramp up output in the next three to five years — in light of rising pharmaceutical demand and new product launches — with little to no incremental capital expenditure, thus potentially leading to better economies of scale and margins,” it said.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 1. in US

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

V S Industry’s counter measures prove effectivePETALING JAYA: V S Industry Bhd is projected to sustain a positive outlook on revenue growth despite rising cost pressures and labour shortages, which had caused a decline in its operating efficiency.
Source: staronline - 🏆 4. / 75 Read more »